Topical Collection "Biomarkers in Medicine"

Editors

Guest Editor
Prof. Dr. Ludmilla Morozova-Roche

Department of Medical Biochemistry and Biophsyics, Umeå Univeristy, Umeå, SE 90187, Sweden
Website | E-Mail
Interests: biodiagnostics; amyloid; protein misfolding; neuroinflammation; cellular toxicity; neurodegenerative diseases; blood serum; CSF; bioimaging
Guest Editor
Dr. Cornelis F.M. Sier

Departments of Surgery, Leiden University Medical Center Building 1, C4, P.O. Box 9600, 2300 RC Leiden, The Netherlands
Website | E-Mail
Interests: biomarkers; cancer; metastasis; bone healing; angiogenesis; inflammation; cell–cell interactions; proteinases; growth factors; extracellular vesicles; diagnosis; prognosis; imaging; animal models

Topical Collection Information

Dear Colleagues,

The Topical Collection, "Biomarkers", will be focused on the diagnostics of a plethora of pathologies using biomarkers in the blood, cerebrospinal fluid (CSF), and other body fluids. These diseases include widely-spread ailments, such as cancer, diabetes, neurodegenerative Alzheimer’s, Parkinson’s, as well as other pathological conditions. Due to the growing elderly population, these diseases are on the rise in modern society and combatting them is a global issue. Early, or even pre-clinical, diagnostics of pathological conditions at the stage when the clinical symptoms are not yet obvious are of significant therapeutic value, and would enable administration of protective or preventive treatments. This may lead to a significant reduction in the social and healthcare costs of these diseases, as early diagnostics will culminate in more efficient treatment.

The molecular constitution of blood and other body fluids has been shown to be highly representative of the physiological state of an individual. Body-fluid specimen analyses (liquid biopsies) are minimally invasive and a relatively cheap means of early disease detection and convenient monitoring of disease response to therapeutic intervention. These approaches are tightly aligned with the concept of personalized healthcare. Over the last few years, a range of new biomarkers, associated with disease pathology, were discovered, and an arsenal of novel robust diagnostic assays for the (presymptomatic) detection of pathological conditions was established. Biodiagnostics is a rapidly expanding field, yet many questions and problems need to be solved. Some soluble candidate biomarkers failed to demonstrate clinical utility, which may be caused by insufficient association with the disease, or because their validation has been limited to a subset of patients, or by technical limitations in the detection methods.

The present Topical Collection aims at bringing primary research and review articles together to summarize state-of-the-art problems, solutions, and future directions in the biomarker and biodiagnostics field, based on the analysis of various body fluids. Your contribution is very welcome!

Prof. Dr. Ludmilla Morozova-Roche
Dr. Cornelis F.M. Sier
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Ascites
  • Biomarkers
  • Biosensor assay
  • Diagnostics
  • Blood analysis
  • Cancer
  • Cerebrospinal fluid
  • Circulating tumor Cell
  • DNA, miRNA
  • Diabetes
  • Disease monitoring
  • Exosome
  • Liquid biopsy
  • Microvesicle
  • Neoplasia
  • Neurodegenerative disease
  • Metastasis
  • Plasma
  • Point of care device
  • Presymptomatic detection
  • Serum
  • Sputum
  • Tumor marker
  • Urine

Published Papers (3 papers)

2018

Jump to: 2017

Open AccessArticle Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis
Diagnostics 2018, 8(3), 44; https://doi.org/10.3390/diagnostics8030044
Received: 31 May 2018 / Revised: 14 June 2018 / Accepted: 20 June 2018 / Published: 5 July 2018
PDF Full-text (223 KB) | HTML Full-text | XML Full-text
Abstract
Two-dimensional difference gel electrophoresis (2D-DIGE) has been used for identification of possible biomarkers in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients. However, in different studies inconsistent results have been obtained. We wanted to analyze the diagnostic value of 2D-DIGE in early
[...] Read more.
Two-dimensional difference gel electrophoresis (2D-DIGE) has been used for identification of possible biomarkers in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients. However, in different studies inconsistent results have been obtained. We wanted to analyze the diagnostic value of 2D-DIGE in early MS patients by comparing protein patterns between single and pooled samples of MS patients and controls. CSF samples of 20 MS patients and 10 control subjects were processed with 2D-DIGE. The so obtained protein patterns were analyzed with DeCyder 6.5 software, whereby we described variation of patterns presented in one gel as well as between different gels. Even when running single samples of patients of the same group in one gel, variation of protein patterns was high. The number of identified spots with different protein level varied between 4 and 30, depending on which sample batches were compared. We did not find a consistent pattern throughout all possible batch combinations. The inter-individual variation of protein expression as well as the susceptibility of 2D-DIGE for methodological variations makes use of 2D-DIGE as a diagnostic tool for MS and for detection of possible candidate biomarkers difficult, since detected proteins vary depending on which samples are compared. Full article

2017

Jump to: 2018

Open AccessReview Single Domain Antibodies as New Biomarker Detectors
Diagnostics 2017, 7(4), 52; https://doi.org/10.3390/diagnostics7040052
Received: 23 August 2017 / Revised: 7 September 2017 / Accepted: 8 September 2017 / Published: 17 October 2017
PDF Full-text (1111 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Biomarkers are defined as indicators of biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. Biomarkers have been widely used for early detection, prediction of response after treatment, and for monitoring the progression of diseases. Antibodies represent promising tools for recognition
[...] Read more.
Biomarkers are defined as indicators of biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. Biomarkers have been widely used for early detection, prediction of response after treatment, and for monitoring the progression of diseases. Antibodies represent promising tools for recognition of biomarkers, and are widely deployed as analytical tools in clinical settings. For immunodiagnostics, antibodies are now exploited as binders for antigens of interest across a range of platforms. More recently, the discovery of antibody surface display and combinatorial chemistry techniques has allowed the exploration of new binders from a range of animals, for instance variable domains of new antigen receptors (VNAR) from shark and variable heavy chain domains (VHH) or nanobodies from camelids. These single domain antibodies (sdAbs) have some advantages over conventional murine immunoglobulin owing to the lack of a light chain, making them the smallest natural biomarker binders thus far identified. In this review, we will discuss several biomarkers used as a means to validate diseases progress. The potential functionality of modern singe domain antigen binders derived from phylogenetically early animals as new biomarker detectors for current diagnostic and research platforms development will be described. Full article
Figures

Figure 1

Open AccessArticle Comparison of Direct Sequencing, Real-Time PCR-High Resolution Melt (PCR-HRM) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) Analysis for Genotyping of Common Thiopurine Intolerant Variant Alleles NUDT15 c.415C>T and TPMT c.719A>G (TPMT*3C)
Diagnostics 2017, 7(2), 27; https://doi.org/10.3390/diagnostics7020027
Received: 19 April 2017 / Revised: 5 May 2017 / Accepted: 9 May 2017 / Published: 12 May 2017
Cited by 2 | PDF Full-text (581 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Thiopurine intolerance and treatment-related toxicity, such as fatal myelosuppression, is related to non-function genetic variants encoding thiopurine S-methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15). Genetic testing of the common variants NUDT15:NM_018283.2:c.415C>T (Arg139Cys, dbSNP rs116855232 T allele) and TPMT: NM_000367.4:c.719A>G (TPMT*3C, dbSNP rs1142345 G
[...] Read more.
Thiopurine intolerance and treatment-related toxicity, such as fatal myelosuppression, is related to non-function genetic variants encoding thiopurine S-methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15). Genetic testing of the common variants NUDT15:NM_018283.2:c.415C>T (Arg139Cys, dbSNP rs116855232 T allele) and TPMT: NM_000367.4:c.719A>G (TPMT*3C, dbSNP rs1142345 G allele) in East Asians including Chinese can potentially prevent treatment-related complications. Two complementary genotyping approaches, real-time PCR-high resolution melt (PCR-HRM) and PCR-restriction fragment length morphism (PCR-RFLP) analysis were evaluated using conventional PCR and Sanger sequencing genotyping as the gold standard. Sixty patient samples were tested, revealing seven patients (11.7%) heterozygous for NUDT15 c.415C>T, one patient homozygous for the variant and one patient heterozygous for the TPMT*3C non-function allele. No patient was found to harbor both variants. In total, nine out of 60 (15%) patients tested had genotypic evidence of thiopurine intolerance, which may require dosage adjustment or alternative medication should they be started on azathioprine, mercaptopurine or thioguanine. The two newly developed assays were more efficient and showed complete concordance (60/60, 100%) compared to the Sanger sequencing results. Accurate and cost-effective genotyping assays by real-time PCR-HRM and PCR-RFLP for NUDT15 c.415C>T and TPMT*3C were successfully developed. Further studies may establish their roles in genotype-informed clinical decision-making in the prevention of morbidity and mortality due to thiopurine intolerance. Full article
Figures

Graphical abstract

Back to Top